JP2023532273A5 - - Google Patents

Info

Publication number
JP2023532273A5
JP2023532273A5 JP2022579927A JP2022579927A JP2023532273A5 JP 2023532273 A5 JP2023532273 A5 JP 2023532273A5 JP 2022579927 A JP2022579927 A JP 2022579927A JP 2022579927 A JP2022579927 A JP 2022579927A JP 2023532273 A5 JP2023532273 A5 JP 2023532273A5
Authority
JP
Japan
Prior art keywords
bispecific
cytokine fusion
fusion according
cancer
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/050872 external-priority patent/WO2021258213A1/en
Publication of JP2023532273A publication Critical patent/JP2023532273A/ja
Publication of JP2023532273A5 publication Critical patent/JP2023532273A5/ja
Priority to JP2026064153A priority Critical patent/JP2026120639A/ja
Pending legal-status Critical Current

Links

JP2022579927A 2020-06-24 2021-06-24 二重特異性スーパーカイン及びその使用 Pending JP2023532273A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026064153A JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063043227P 2020-06-24 2020-06-24
US63/043,227 2020-06-24
US202063093724P 2020-10-19 2020-10-19
US63/093,724 2020-10-19
US202063094322P 2020-10-20 2020-10-20
US63/094,322 2020-10-20
US202163165600P 2021-03-24 2021-03-24
US202163165738P 2021-03-24 2021-03-24
US63/165,600 2021-03-24
US63/165,738 2021-03-24
PCT/CA2021/050872 WO2021258213A1 (en) 2020-06-24 2021-06-24 Bifunctional superkines and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026064153A Division JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Publications (2)

Publication Number Publication Date
JP2023532273A JP2023532273A (ja) 2023-07-27
JP2023532273A5 true JP2023532273A5 (cg-RX-API-DMAC7.html) 2024-07-01

Family

ID=79282489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022579927A Pending JP2023532273A (ja) 2020-06-24 2021-06-24 二重特異性スーパーカイン及びその使用
JP2026064153A Pending JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026064153A Pending JP2026120639A (ja) 2020-06-24 2026-04-09 二重特異性スーパーカイン及びその使用

Country Status (6)

Country Link
US (1) US20230365642A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172216A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023532273A (cg-RX-API-DMAC7.html)
CN (1) CN116390744A (cg-RX-API-DMAC7.html)
CA (1) CA3183825A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021258213A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015KN00329A (cg-RX-API-DMAC7.html) 2012-08-09 2015-07-10 Univ Leland Stanford Junior
JP6936934B2 (ja) 2013-09-24 2021-09-22 メディシナ セラピューティクス インコーポレイテッド インターロイキン−4受容体結合融合タンパク質及びその使用
CA3078434A1 (en) 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
WO2019232523A1 (en) 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
JP7819944B2 (ja) * 2020-07-09 2026-02-25 ユーティレックス カンパニー リミテッド Il-2バリアント
US12702710B2 (en) 2020-10-12 2026-08-11 Medicenna Therapeutics Inc. Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
TW202317623A (zh) * 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
KR20250004954A (ko) * 2022-03-08 2025-01-09 메디세나 테라퓨틱스, 인크. Il-2, il-13, 및 il-4 시토킨 이작용성 분자의 용도 및 방법
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023248009A1 (en) * 2022-06-21 2023-12-28 Medicenna Therapeutics, Inc. Dosing methods for use with il-2 superagonists, agonists, and fusions thereof
WO2024073435A2 (en) * 2022-09-27 2024-04-04 Anwita Biosciences, Inc. Anti-lag-3/il-2 fusion proteins, encoding polynucleotides, pharmaceutical compositions, and therapeutic applications
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
CN121816367A (zh) * 2023-06-27 2026-04-07 梅迪塞纳医疗股份有限公司 Il-2融合蛋白
EP4770754A1 (en) 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512194B2 (en) * 2012-01-27 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Modified IL-13 polypeptides
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
WO2019239213A2 (en) * 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2019232523A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
TW202128961A (zh) * 2019-11-20 2021-08-01 美商安維塔生物科學股份有限公司 細胞激素融合蛋白及其醫藥組合物及治療應用

Similar Documents

Publication Publication Date Title
JP2020524174A5 (cg-RX-API-DMAC7.html)
Chang et al. Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells
DeVita et al. The chemotherapy of lymphomas: looking back, moving forward—the Richard and Hinda Rosenthal Foundation award lecture
Hoyos et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
Ouladan et al. Chimeric antigen receptor-T cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy
Dasgupta et al. Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer
JP2020522254A5 (cg-RX-API-DMAC7.html)
Kuo et al. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells
Buhmann et al. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial
JP2021524756A5 (cg-RX-API-DMAC7.html)
JP2022521937A5 (cg-RX-API-DMAC7.html)
Asano et al. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody
JP2018502050A5 (cg-RX-API-DMAC7.html)
JP2022532490A5 (cg-RX-API-DMAC7.html)
Warmuth et al. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
JP7548924B2 (ja) がんの処置における増強された有効性のためのil-4/il-13経路阻害剤
Lutz et al. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
Zorko et al. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Liu et al. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities
Prodi et al. Tumor-homing antibody-cytokine fusions for cancer therapy
Yu et al. Development of a tetravalent T-cell engaging bispecific antibody against glypican-3 for hepatocellular carcinoma
Zhao et al. Current status and future perspective of natural killer cell therapy for cancer
WO2024082269A1 (zh) 双特异性抗体在免疫细胞治疗方面的应用
Lum et al. Activated T-cell and bispecific antibody immunotherapy for high-risk breast cancer bench to bedside